| Project/Area Number |
08044277
|
|---|
| Research Category |
Grant-in-Aid for international Scientific Research
|
| Allocation Type | Single-year Grants |
|---|
| Section | Joint Research |
|---|
| Research Institution | KYOTO UNIVERSITY |
|---|
Principal Investigator |
SAITO Yoshihiko Kyoto Univ., Grad.Sc.of Med., Assistant Professor, 医学研究科, 助手 (30250260)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MASUDA Izuru kyoto Univ., Grad.Sc.of Med., Assistant Professor, 医学研究科, 助手 (10229370)
NAKAO Kazuwa Kyoto Univ., Grad.Sc.of Mcd., Professor, 医学研究科, 教授 (00172263)
THOMAS Hedner Schlgenska Univ.Hospital.Dept.of Pharmacology, Professor and Chairman, Depertme, Professor
CHIーMING Wei Depertment of Surgery, School of Medicine, Associate
JOHN.C Burne Mayo Clinic, Cardorenal Res. Labo., Director a
JOHN C Burnett Jr Mayo Clinic, Cardiorenal Res.Lab., Director and Professor
WEI Chi-Min Univ.of Maryland sc.of Med., Dept.of Surgery, Associate Professor
城ヶ崎 倫久 Mayo Clilic, Cardiorenal Research Laborat, Research F
HEDNER Thoma Schlgrenska University Hospital, Depertme, Professor
WEI ChiーMing University of MarylandSchool of Medicine, Associate
BURNETT John Mayo Clinic, Cardiorenal Res. Labo., Director a
|
|---|
| Project Period (FY) |
1996
|
| Project Status |
Completed (Fiscal Year 1996)
|
| Budget Amount *help |
¥6,000,000 (Direct Cost: ¥6,000,000)
Fiscal Year 1996: ¥6,000,000 (Direct Cost: ¥6,000,000)
|
|---|
| Keywords | ANP / BNP / Congestive heart failure / hypertrophy / cohort |
|---|
| Research Abstract |
Heart failure is the pathological state in which the heart is unable to pump blood to vaital organs and thereby sometimes causes the death.
Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are cardiac hormones, posessing natriuretic, diuretic and vasodilating activities. Accumulating evidence indicates that the natriuretic peptide system especially, ANP and BNP,is clinically useful for not only the diagnosis of heart diseases but also treatment of congestive heart failure.
To further evaluate clinical usefulness of natriuretic peptides in cardiac diseases, we organize three kinds of large scale cooperative studies in Japan, United States of America and Sweden.
The first study was designed to prospectively determine whether one of the natriuretic peptides-ANP or BNP-is superior to another for ditection of left ventricular dysfunction in 94 consecutive patients referred for cardiac catheterization. The elevated plasma BNP concentration was a more powerful marker of left
… More
ventricular systolic, diastolic dysfunction and left ventricular hypertrophy evaluated by echocardiography than the elevated plasma ANP level.
in the second study, to evaluate whether the plasma BNP level predicts mortality in old population, we3 measured the plasma BNP level in 541 subjects from the 85-year old population in Gothenburg, Sweden. We found that the incr ased BNP level significantly predicted 5-years mortality in the total population. In subjects witl a known cardiovascular disorder, 5-yeare mortality was significantly correlated with the ele ated plasma BNP level.
In the third study, we examined the effect of a long-term infusion of ANP on hemodynamics and renal functions in patients with congestive heart failure. Although the short-term infusion of ANP was reported to improve congestive heart failure, the long-term infusion of ANP decreased preload and increased urine volume. In spite of the diuretic action, the long-term infusion of ANP did not deteriorate serum electrolyte balance. Any side effects were observed during the infusion.
We concluded that natriuretic peptides are clinically useful for diagnosis and treatment of cardiovascular diseases. Less
|
